William Shakespeare - Nov 6, 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
President of Research and Development
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Stock symbol
THRX
Transactions as of
Nov 6, 2023
Transactions value $
$80,347
Form type
4
Date filed
11/7/2023, 04:03 PM
Previous filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction THRX Common Stock Options Exercise $80.3K +251K +64.66% $0.32* 639K Nov 6, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Options Exercise $0 -251K -72.92% $0.00 93.3K Nov 6, 2023 Common Stock 251K $0.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.

Remarks:

President of Research and Development